J&J: wins FDA breakthrough therapy for cancer treatment
(CercleFinance.com) - Johnson & Johnson's Janssen has received breakthrough therapy designation from the US Food and Drug Administration for an investigational treatment for metastatic urothelial cancer, one of the most common forms of cancers, the drugmaker said on Thursday.
Erdafitinib, an oral pan-fibroblast growth factor receptor tyrosine kinase inhibitor, showed promising results in the treatment of this form of bladder cancer, the sixth most common type of cancer in the US, Janssen said.
A breakthrough therapy designation is granted to accelerate the regulatory review of investigational medicines that intend to treat serious or life-threatening diseases.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Erdafitinib, an oral pan-fibroblast growth factor receptor tyrosine kinase inhibitor, showed promising results in the treatment of this form of bladder cancer, the sixth most common type of cancer in the US, Janssen said.
A breakthrough therapy designation is granted to accelerate the regulatory review of investigational medicines that intend to treat serious or life-threatening diseases.
Copyright (c) 2018 CercleFinance.com. All rights reserved.